ReviewCurrent urology reports2019
What's New in Rezum: a Transurethral Water Vapour Therapy for BPH.
Review in Current urology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Convective radiofrequency water vapour thermal therapy for lower urinary tract symptoms in men with benign prostatic hyperplasia.The Cochrane database of systematic reviews · 2020Pooled it
- Water Vapor Thermal Therapy for Benign Prostatic Hyperplasia: An Umbrella Review and Updated Meta-Analysis.The world journal of men's health · 2026Article
- Comparing complications of Rezum and Urolift for BPH/LUTS using the Accordion Severity Grading System.International urology and nephrology · 2026Article
- Emphysematous sloughed floating ball after prostate water vaporization Rezum: A case report.World journal of clinical cases · 2023Article
- Surgical Complications in the Management of Benign Prostatic Hyperplasia Treatment.Current urology reports · 2022Review
- Water vapor therapy (Rezūm) for lower urinary tract symptoms related to benign prostatic hyperplasia: early results from the first Italian multicentric study.World journal of urology · 2021Article
- Rezum: a novel minimally invasive treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. A review article.International urology and nephrology · 2021Review
- Article
- Rezum therapy for patients with large prostates (≥ 80 g): initial clinical experience and postoperative outcomes.World journal of urology · 2021Article
- Reasons for new MIS. Let's be fair: iTIND, Urolift and Rezūm.World journal of urology · 2021Review
- Online interest in surgical treatment for benign prostatic hyperplasia using Google trends.World journal of urology · 2021Article
- "Doc, if it were you, what would you do?": a survey of Men's Health specialists' personal preferences regarding treatment modalities.International journal of impotence research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewRezum is a new minimally invasive treatment for benign prostate enlargement using thermal transurethral water vapour therapy. We review the evidence with advantages and disadvantages of this technique. RECENT
findingsThere are five studies reported including a randomised control trial looking at the outcomes of Rezum. The outcomes show an IPSS reduction by 45-60%, QoL improvement with a score reduction of 37-59%, the Qmax improvement by 44-72% and the PVR reduction by 20-38%. Convective water vapour therapy using the Rezum system has been shown to have successful outcomes in the treatment of LUTS resulting from BPH. The reported complications are infrequent and often minor, and it seems to be relatively cost-effective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.